Jim Simons Krystal Biotech, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 14,400 shares of KRYS stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,400

Holding current value

$2.28 Million

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$174.7 - $213.66 $2.52 Million - $3.08 Million	14,400 New	14,400 $2.62 Million
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $2.67 Million - $4.43 Million	24,700 New	24,700 $4.4 Million
Q4 2021 Feb 11, 2022	SELL	$39.81 - $88.24 $1.33 Million - $2.94 Million	-33,300 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $1.73 Million - $2.39 Million	33,300 New	33,300 $1.74 Million
Q4 2020 Feb 10, 2021	SELL	$40.64 - $61.38 $796,544 - $1.2 Million	-19,600 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$37.76 - $48.49 $1.58 Million - $2.03 Million	-41,800 Reduced 68.08%	19,600 $844,000
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $2.05 Million - $3.32 Million	55,400 Added 923.33%	61,400 $2.54 Million
Q1 2020 May 14, 2020	BUY	$35.02 - $65.64 $210,120 - $393,840	6,000 New	6,000 $259,000
Q2 2019 Aug 12, 2019	SELL	$27.2 - $41.2 $837,760 - $1.27 Million	-30,800 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$19.86 - $32.9 $220,446 - $365,190	-11,100 Reduced 26.49%	30,800 $1.01 Million
Q4 2018 Feb 13, 2019	BUY	$15.03 - $25.38 $629,757 - $1.06 Million	41,900 New	41,900 $871,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.07B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account